This inventor holds 1 USPTO granted patent and 1 published patent application, plus 6 CIPO patents and 7 EPO patents. Top assignee: Boehringer Ingelheim International Gmbh. Active years: 2015.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2015
Title: Bernd Plohmann: Innovator in Aqueous Composition for Secretolytic Therapy
Introduction
Bernd Plohmann is a notable inventor based in Ingelheim am Rhein, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the development of aqueous compositions for therapeutic use. His innovative work has led to the filing of a patent that addresses important medical needs.
Latest Patents
Plohmann holds a patent for an "Aqueous composition comprising bromhexine." This invention relates to aqueous compositions containing bromhexine, which includes an amount of sugar alcohols of less than 10 g based on 100 ml of the composition. The primary application of this composition is for secretolytic therapy in acute and chronic bronchopulmonary disorders. This patent highlights his commitment to improving respiratory health through innovative solutions.
Career Highlights
Throughout his career, Bernd Plohmann has worked with prominent companies in the pharmaceutical industry. He has been associated with Boehringer Ingelheim International GmbH and Sanofi-Aventis Deutschland GmbH. His experience in these organizations has allowed him to develop and refine his expertise in drug formulation and therapeutic applications.
Collaborations
Plohmann has collaborated with several professionals in his field, including Uwe Scheuring and Annette Zamponi. These collaborations have contributed to the advancement of his research and the successful development of his patented compositions.
Conclusion
Bernd Plohmann is a distinguished inventor whose work in aqueous compositions has the potential to significantly impact the treatment of bronchopulmonary disorders. His innovative approach and dedication to pharmaceutical advancements are commendable.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
